Caribou Biosciences Reports Third Quarter 2026 Financial Results
Caribou Biosciences reported its financial results for the third quarter of 2026, highlighting a net loss of $26.6 million and ongoing strategic restructuring efforts.
Stocks · News reference
Caribou Biosciences Announces Acceptance of Clinical Abstracts for 2026 ASH Annual Meeting
Caribou Biosciences announced that clinical abstracts for its vispa-cel and CB-011 programs have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Analysts downgraded STZ, TYL, DK, CRBU and PSX; price targets changed for STZ, TYL, DK and PSX.
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Neutral.